Eisai To Distribute Ajinomoto Drugs In 11 Asian Nations Outside Japan
This article was originally published in PharmAsia News
Executive Summary
Japan's Ajinomoto has arranged for Esai to distribute its Livact Granules (amino acid) hepatic liver cirrhosis drug in Asian countries outside Japan. The two companies also are discussing having Esai get approval for and distribute other Ajinomoto digestive system drugs abroad as part of the company's goal of a 20 percent sales increase. The Livact agreement calls for Esai to target nine countries: Cambodia, China, India, Indonesia, Malaysia, Myanmar, the Philippines, Singapore, Sri Lanka, Thailand and Vietnam. (Click here for more - a subscription may be required
You may also be interested in...
Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line
The French drugmaker has identified education as a key challenge ahead of its June action date for the huge-selling IL4/IL-13 inhibitor in the lung condition. An approval would make it the first biologic for the disease.
Global Pharma Guidance Tracker – March 2024
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.
EU Stakeholders Devise Six-Point Plan To Improve Cross-Border Clinical Trials
Sponsors need guidance on ethics requirements and clarity around national regulations to conduct cross-border clinical trials in the EU, a multi-stakeholder forum says.